Treats a person's own blood with a measured dose of ozone gas, then returns it, aiming to activate the body's antioxidant and repair systems through a brief, controlled chemical stress. The strongest evidence sits in specific conditions like joint pain, chronic wounds, and severe viral illness; the longevity benefit in healthy people remains untested. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Glucose-6-phosphate dehydrogenase (G6PD) | Normal enzyme activity (not deficient) | Identifies risk of red-cell breakdown from oxidation |
| Complete blood count (hemoglobin, hematocrit) | Hemoglobin ~13.5–15 g/dL (men), ~12.5–14 g/dL (women) | Detects anemia at baseline and hemolysis during treatment |
| High-sensitivity C-reactive protein (hs-CRP) | < 1.0 mg/L | Tracks systemic inflammation, a proposed target of therapy |
| Interleukin-6 (IL-6) | Low-normal (assay-dependent, often < 2 pg/mL) | Marker of inflammatory signaling reported to fall with ozone |
| Fasting glucose / HbA1c | Glucose 70–90 mg/dL; HbA1c < 5.4% | Relevant where metabolic or wound-healing benefit is sought |
| Oxidized LDL or total antioxidant capacity | Lower oxidized LDL; higher antioxidant capacity | Reflects oxidative balance the therapy aims to improve |
Cadence: Reassess after the initial block of sessions (4–6 weeks), then every 3–6 months during any maintenance phase; recheck red-cell parameters if higher concentrations are used.